Enrolment | Treatment period | Follow-up period | |||||||||||
Day | −10 | 0 | 7 | 10 | 14 | 17 | 21 | 28 | 42 | 56 | 84 | 112 | 168 |
Time point | Visit | Visit | Visit | Visit | Visit | Visit | Visit | Visit | Tele | Tele | Visit | Tele | Visit |
Informed consent | ✘ | ||||||||||||
Eligibility screening | ✘ | ||||||||||||
Allocation | ✘ | ||||||||||||
T&CM + NRT | |||||||||||||
NRT | |||||||||||||
Demographic characteristics | ✘ | ||||||||||||
Physical examination | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ||||||
Smoking-related variables | ✘ | ||||||||||||
Amount of smoking | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | |
Tobacco craving | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | |
FTND | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ||||
Exhaled CO | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ||||
MNWS | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | ||||
EQ-5D, EQ-VAS | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | |||||||
Pulmonary function test | ✘ | ✘ | ✘ | ||||||||||
Compliance | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | |||||||
Adverse events | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | |||||||
Concomitant medication | ✘ | ✘ | ✘ | ✘ | ✘ | ✘ | |||||||
Satisfaction | ✘ | ||||||||||||
Non-smoking efforts | ✘ | ✘ | ✘ | ✘ | ✘ | ||||||||
Treatment history | ✘ | ✘ | ✘ | ✘ | ✘ |
CO, carbon monoxide; EQ-5D, EuroQol five dimension questionnaire; EQ-VAS, EuroQol visual analogue scale; FTND, Fagerstrom Test for Nicotine Dependence; MNWS, Minnesota Nicotine Withdrawal Scale; NRT, nicotine replacement therapy; T&CM, traditional and complementary medicine; tele, telephone.